Corporate VCs Star In Financings Of The Fortnight
This article was originally published in The Pink Sheet Daily
Executive Summary
Probiodrug, Pulmatrix, Virdante all gain new money from corporate ventures.
You may also be interested in...
What Dry Spell? 5AM Closes $200 M Fund
As its life-science peers stumble, the early-stage investment firm raises a third fund with 33 percent more committed than its previous fund.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.